{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04999449",
            "orgStudyIdInfo": {
                "id": "STUDY02001115"
            },
            "organization": {
                "fullName": "Dartmouth-Hitchcock Medical Center",
                "class": "OTHER"
            },
            "briefTitle": "Nebulizer Delivery of Intranasal Scopolamine",
            "officialTitle": "Nebulizer Delivery of Intranasal Scopolamine",
            "therapeuticArea": [
                "Other"
            ],
            "study": "nebulizer-delivery-of-intranasal-scopolamine"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-01-24",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-08",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-08",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-08-02",
            "studyFirstSubmitQcDate": "2021-08-07",
            "studyFirstPostDateStruct": {
                "date": "2021-08-10",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-07-28",
            "lastUpdatePostDateStruct": {
                "date": "2023-08-01",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Jay C. Buckey Jr.",
                "investigatorTitle": "Professor of Medicine",
                "investigatorAffiliation": "Dartmouth-Hitchcock Medical Center"
            },
            "leadSponsor": {
                "name": "Dartmouth-Hitchcock Medical Center",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "To develop a better way to administer anti-motion sickness medications using an intranasal nebulizer."
        },
        "conditionsModule": {
            "conditions": [
                "Scopolamine",
                "Motion Sickness"
            ],
            "keywords": [
                "Scopolamine",
                "Motion Sickness",
                "Space Physiology"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "interventionModelDescription": "Pharmacokinetic study followed by double-blind, placebo-controlled, dose-ranging design",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 30,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Pharmacokinetic",
                    "type": "EXPERIMENTAL",
                    "description": "Participants receive 1 dose of Scopolamine 0.4 mg delivered via a intranasal nebulizer developed by Creare LLC.",
                    "interventionNames": [
                        "Drug: Scopolamine"
                    ]
                },
                {
                    "label": "Chair",
                    "type": "EXPERIMENTAL",
                    "description": "Participants receive 1 dose of Scopolamine 0.2 mg, 1 dose of Scopolamine 0.4 mg, and 1 dose of placebo saline delivered via the Creare LLC intranasal nebulizer. These dosages are all 1 week apart and the order is randomized.",
                    "interventionNames": [
                        "Drug: Scopolamine",
                        "Drug: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Scopolamine",
                    "description": "Intranasal scopolamine at 0.2 mg or 0.4 mg",
                    "armGroupLabels": [
                        "Chair",
                        "Pharmacokinetic"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "Intranasal saline placebo",
                    "armGroupLabels": [
                        "Chair"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Time to maximal concentration for scopolamine after intranasal administration (Tmax)",
                    "description": "Plasma scopolamine concentrations will be measured using an liquid chromatography-mass spectrometry (LC- MS) assay. Tmax is measured in minutes to reach the maximum concentration.",
                    "timeFrame": "Baseline, 180 minutes"
                },
                {
                    "measure": "Side effects of intranasal scopolamine, as measured through a questionnaire with a subjective rating scale",
                    "description": "A questionnaire will be administered asking about the participant's side effect profile after taking intranasal scopolamine. The questionnaire will have a subjective rating scale of 0-10 on the potential scopolamine side effects expected",
                    "timeFrame": "180 minutes"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Effectiveness in reducing motion sickness as measured by duration of chair ride.",
                    "description": "The degree of motion sickness will be assessed by measuring the total number of minutes the subject rides in the chair before stopping",
                    "timeFrame": "Baseline, end of chair ride (maximum of 20 minutes)"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Male or female\n* Adults age 21-49\n* Normal weight for body size, based on BMI table\n* General good health, as determined by a verbally provided medical history\n* Normal brief neurological exam\n* Renal and hepatic function within normal ranges\n* Able to provide written informed consent to participate\n\nExclusion Criteria:\n\n* Drug allergies to scopolamine or other belladonna alkaloid\n* Use of medications within 1 week of starting the study\n* Use of an investigational drug within 30 days of starting the study\n* Tobacco smoking within the past year\n* Blood donation or significant blood loss within 30 days of starting the study\n* Significant gastrointestinal disorder (e.g. Crohn's Disease, ulcerative colitis, chronic constipation), asthma, glaucoma, prostate problems, urinary obstruction, or seizure disorders\n* History of alcohol or other drug abuse\n* Pregnancy or suspected pregnancy, or lactation (pregnancy will be confirmed with urine pregnancy testing prior to drug administration)\n* Consumption of grapefruit juice within 7 days of scopolamine (SCOP) administration\n* Nasal, nasal sinus, or nasal mucosa surgery within 90 days prior to study initiation\n* Other significant surgeries within 90 days\n* Significant deviated septum that blocks air flow in one nostril\n* Rhinitis, sinus infection, severe allergies, and other upper respiratory infections within 30 days prior to the study\n* Current use of an intranasal medication\n* Wheezing or other respiratory problem\n* Unable to consent\n* Prisoner",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "21 Years",
            "maximumAge": "49 Years",
            "stdAges": [
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Samantha M Leigh, BA",
                    "role": "CONTACT",
                    "phone": "(603) 646-5327",
                    "email": "samantha.m.leigh@dartmouth.edu"
                },
                {
                    "name": "Shireen Geimer, MS",
                    "role": "CONTACT",
                    "phone": "(603) 646-5331",
                    "email": "Shireen.Geimer@dartmouth.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Jay C Buckey, Ph.D",
                    "affiliation": "Dartmouth-Hitchcock Medical Center",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Dartmouth-Hitchcock Medical Center",
                    "status": "RECRUITING",
                    "city": "Lebanon",
                    "state": "New Hampshire",
                    "zip": "03756",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 43.64229,
                        "lon": -72.25176
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009041",
                    "term": "Motion Sickness"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M12002",
                    "name": "Motion Sickness",
                    "asFound": "Motion Sickness",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000012601",
                    "term": "Scopolamine"
                },
                {
                    "id": "D000002086",
                    "term": "Butylscopolammonium Bromide"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000759",
                    "term": "Adjuvants, Anesthesia"
                },
                {
                    "id": "D000000932",
                    "term": "Antiemetics"
                },
                {
                    "id": "D000001337",
                    "term": "Autonomic Agents"
                },
                {
                    "id": "D000018373",
                    "term": "Peripheral Nervous System Agents"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000005765",
                    "term": "Gastrointestinal Agents"
                },
                {
                    "id": "D000009184",
                    "term": "Mydriatics"
                },
                {
                    "id": "D000018680",
                    "term": "Cholinergic Antagonists"
                },
                {
                    "id": "D000018678",
                    "term": "Cholinergic Agents"
                },
                {
                    "id": "D000018377",
                    "term": "Neurotransmitter Agents"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000018727",
                    "term": "Muscarinic Antagonists"
                },
                {
                    "id": "D000010276",
                    "term": "Parasympatholytics"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M15418",
                    "name": "Scopolamine",
                    "asFound": "One side",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5352",
                    "name": "Butylscopolammonium Bromide",
                    "asFound": "One side",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5241",
                    "name": "Bromides",
                    "relevance": "LOW"
                },
                {
                    "id": "M4107",
                    "name": "Anesthetics",
                    "relevance": "LOW"
                },
                {
                    "id": "M4089",
                    "name": "Adjuvants, Anesthesia",
                    "relevance": "LOW"
                },
                {
                    "id": "M4251",
                    "name": "Antiemetics",
                    "relevance": "LOW"
                },
                {
                    "id": "M8881",
                    "name": "Gastrointestinal Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M12139",
                    "name": "Mydriatics",
                    "relevance": "LOW"
                },
                {
                    "id": "M20758",
                    "name": "Cholinergic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M20760",
                    "name": "Cholinergic Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M20504",
                    "name": "Neurotransmitter Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M20801",
                    "name": "Muscarinic Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M13189",
                    "name": "Parasympatholytics",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "AdjAn",
                    "name": "Adjuvants, Anesthesia"
                },
                {
                    "abbrev": "AnEm",
                    "name": "Antiemetics"
                },
                {
                    "abbrev": "Gast",
                    "name": "Gastrointestinal Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "AntiConv",
                    "name": "Anticonvulsants"
                },
                {
                    "abbrev": "CNSDep",
                    "name": "Central Nervous System Depressants"
                }
            ]
        }
    },
    "hasResults": false
}